Is KKR (KKR) Undervalued Following Its Allyntra Platform Launch?
KKR (KKR) is in focus after announcing Allyntra, a new precision engineered solutions platform aimed at medical technology and related markets, with experienced industry leaders appointed to guide expansion and integration plans.
See our latest analysis for KKR.
Despite the Allyntra launch and KKR’s interest in Qiagen and European fiber assets, momentum in the stock price has been weak. The 1-day share price return is down 3.93%, the 90-day share price return is down 7.16%, and the year-to-date share price return is down 24.77%, even though the 3-year total shareholder return is 62.94% and the 5-year total shareholder return is 63.61%.
If this kind of deal activity has your attention, it can be useful to widen the lens and see what else is happening across private equity backed businesses by checking a curated set of 18 top founder-led companies
After a sharp pullback in KKR despite a solid multi year track record, investors are left weighing a simple tension: is most of the stock’s upside already in the rearview mirror, or does current pricing still leave room ahead?
Most Popular Narrative: 14.8% Overvalued
The current KKR share price of $96.97 sits above a narrative fair value of $84.45, so the story behind that gap matters for long term investors.
Desde un enfoque Buffett puro:
KKR empieza a parecer menos un gestor de private equity y más un “compounder de capital permanente”.
The core of this KKR narrative is simple but punchy. It leans heavily on recurring fee earnings, long duration capital and an assumed step up in profitability. Curious how those ingredients combine into the fair value range and what has been left out on purpose.
Result: Fair Value of $84.45 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this KKR narrative still faces clear risks, including a sharp deterioration in private credit portfolios or weaker fundraising that pressures fee-based, recurring earnings.
Find out about the key risks to this KKR narrative.
Another View On KKR’s Valuation
The narrative-based fair value for KKR suggests the stock is 14.8% overvalued at $96.97 versus $84.45, but our DCF model points in a different direction. On that framework, KKR is trading below an estimated future cash flow value of $119.53, which indicates an undervalued setup instead. Which perspective do you think better fits your risk tolerance?
For a closer look at how the cash flow assumptions compare with the market price, including the role of recurring earnings and insurance income, Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out KKR for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 45 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
With KKR throwing up mixed signals, do you want to rely on others’ narratives or test the data yourself and move quickly to your own view? To see what optimism in the story is based on, take a closer look at the 3 key rewards.
Looking for more investment ideas beyond KKR?
If KKR has you thinking harder about portfolio quality, do not stop here. Broaden your watchlist with other focused stock ideas built from the same data driven engine.
- Target reliable cash generators by scanning companies with the 45 high quality undervalued stocks.
- Strengthen your income stream by reviewing potential high yield opportunities through the 9 dividend fortresses.
- Dial down risk by zeroing in on companies that pass strict balance sheet checks in the solid balance sheet and fundamentals stocks screener (48 results).
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com